

IN THE CLAIMS

Claims 1-270 (canceled)

271. **(previously presented)** A method of treating an ophthalmologic disorder characterized by an accumulation of retinotoxic compounds in the cells of the retinal pigment epithelium in a subject comprising administering to the subject a pharmaceutically acceptable amount of fenretinide or a pharmaceutically acceptable salt thereof.
272. **(previously presented)** The method of claim 271, wherein fenretinide inhibits, antagonizes, or short-circuits the visual cycle at a step of the visual cycle that occurs outside a disc of a rod photoreceptor cell.
273. **(previously presented)** The method of claim 271, wherein the ophthalmologic disorder is macular degeneration.
274. **(withdrawn)** The method of claim 271, wherein the ophthalmologic disorder is Stargardt's disease.
275. **(withdrawn)** The method of claim 271, wherein the ophthalmologic disorder is lipofuscin accumulation.

Claims 276-279 (canceled)